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Background: Increased small airway resistance and decreased lung elasticity contribute to the airflow limitation in
chronic obstructive pulmonary disease (COPD). The lesion that corresponds to loss of lung elasticity is emphysema;
the small airway obstruction is due to inflammatory narrowing and obliteration. Despite their convergence in
altered physiology, different mechanisms contribute to these processes. The relationships between gene expression
and these specific phenotypes may be more revealing than comparison with lung function.
Methods: We measured the ratio of alveolar surface area to lung volume (SA/V) in lung tissue from 43 smokers.
Two samples from 21 subjects, in which SA/V differed by >49 cm2/mL were profiled to select genes whose
expression correlated with SA/V. Significant genes were tested for replication in the 22 remaining subjects.
Results: The level of expression of 181 transcripts was related to SA/V ( p < 0.05). When these genes were tested in
the 22 remaining subjects as a replication, thirty of the 181 genes remained significantly associated with SA/V (P < 0.05)
and the direction of association was the same in 164/181. Pathway and network analysis revealed enrichment of genes
involved in protein ubiquitination, and western blotting showed altered expression of genes involved in protein
ubiquitination in obstructed individuals.
Conclusion: This study implicates modified protein ubiquitination and degradation as a potentially important pathway
in the pathogenesis of emphysema.
Keywords: Pulmonary emphysema, Surface area to lung volume ratio, Gene expression, Transcriptional analysis, mRNA,
Cigarette smoking, Protein ubquitinationBackground
The pathology of chronic obstructive pulmonary disease
(COPD) includes 2 main components; chronic obstructive
bronchiolitis with fibrosis which causes narrowing and
ultimately obliteration of small airways, and emphysema
with enlargement of airspaces and destruction of lung
parenchyma which causes loss of lung elasticity [1]. Most
patients with COPD have both lesions although one
may predominate in individual patients. Although the
processes differ substantially they both lead to a com-
mon phenotype, reduced maximal expiratory flow.* Correspondence: Peter.pare@hli.ubc.ca
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article, unless otherwise stated.One method to discover the molecular mechanisms
leading to disease is to compare gene expression pattern
in the organs of affected and non-affected individuals.
However since the gene expression patterns that con-
tribute to airway remodeling and to emphysema may be
different, correlation of gene expression with the individ-
ual lesions, rather than with lung function, may be more
revealing. The degree of emphysema can be measured
microscopically as the lung surface area to volume ratio
(SA/V) [2]. In the current study we identified 181 genes
whose expression pattern correlated with the severity of
emphysema using two samples of lung tissue with differ-
ent SA/V from 21 smokers with variable degrees of air-
flow obstruction whose lungs were resected for small
peripheral lung lesions (P < 0.05). To validate associa-
tions we examined the relationship between expressionntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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samples. 30 of the 181 genes were significantly associ-
ated with SA/V in the replication set. Gene set annota-
tion and pathway analyses showed that genes involved in
protein ubiquitination and the proteasome pathway were
differentially expressed in emphysematous lung tissue.
Protein analysis confirmed the abnormal accumulation
of protein-ubiquitin conjugates and the altered expres-
sion of genes involved in protein ubiquitination in the
lungs of obstructed smokers.
Methods
Subject selection and experimental design
Preoperatively, patients provided informed written con-
sent that a portion of their lung tissue be used for re-
search. The experimental protocols were approved by the
ethics review board of the University of British Columbia
and St Paul’s Hospital. Ethics approval numbers are H00-
50110 and H09-00801. The strategy for selecting patients
for gene profiling has been described in a previous publi-
cation [3] and is detailed in the online supplement. The
frozen lung tissue samples from 43 subjects with a range
of lung function were profiled. In 21 of the subjects 2 sam-
ples, which showed widely different values for SA/V, were
profiled to derive relationships between gene expression
and SA/V. For the remaining 22 subjects, one sample of
lung tissue was profiled and served as a validation data set
for the relationships between gene expression and SA/V.Table 1 Subject characteristics
GOLD stage N Age (yrs) Male/Female Pack years FEV1 %
Non-smokers 4 59 ± 8 2/2 O 90
Control Smokers 18 67 ± 8 11/7 38 ± 19 98
1 9 61 ± 11 6/3 50 ± 14 89
2 9 63 ± 9 6/3 50 ± 21 66
3 3 67 ± 5 2/1 49 ± 12 46
Means ± SD. An ANOVA showed no significant difference in age by GOLD category
DLCO % Predicted. (p < 0.0001 for all comparisons) Among smokers there was no s
Current smokers, GOLD 1 - 6/9 Current smokers. GOLD 2 – 9/10 Current smokers and G
6 months of surgical resection.Lung function measurement
Details of lung function were described previously [3]
and are contained in the online supplement. Briefly,
measures of lung volumes, spirometry and the single breath
diffusing capacity were measured as previously described
and according to ATS standards [4]. Table 1 shows the
number of patients in each GOLD category and their mean
smoking history and lung function.
Tissue processing
Details of tissue processing and determination of SA/V
were described previously [3] and are contained in the
online supplement. Briefly, immediately following resec-
tion the lung or lobe was frozen in liquid nitrogen fumes.
Frozen cores of tissue (1.5 × 2 cm) were obtained from
slices of frozen lung using a power driven hole saw. Fro-
zen sections were obtained from the surface of the ½ core
immediately adjacent to the portion to be used for RNA
extraction. The 10 micron sections were stained with
hematoxylin and eosin and the severity of emphysema in
each core was measured on digital images of the sample
using an in-house point counting program.
Microarray study design and methodology
RNA from 8 GOLD 0 subjects (non-obstructed smokers)
was pooled to form the reference RNA as described [3]
and as detailed in the online supplement. mRNA from
the specimens was profiled using Agilent’s Functionalpredicted FEV1/FVC % DLCO % predicted Diagnoses
± 5 82 ± 3 71 ± 4 4 Carcinoid













± 1 53 ± 9 56 ± 14 1 Adeno (BAC)
1 Squamous
1 Carcinoid
but significant differences for pack years, FEV1 % predicted, FEV1/FVC % and
ignificant difference in pack years by GOLD category. Control smokers – 14/21
OLD 3 – 2 Current smokers and one status unknown. Current smoker =within
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ing was done for 23,757 probe-sets as previously described
[3]. The gene expression data was deposited in Gene
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/
projects/geo/), under the accession number GSE63073.
Since a “batch effect” confounded the results, we per-
formed a very conservative phase/batch adjustment step
before commencing with statistical analysis (see online
supplement).
Statistical analysis
In order to identify genes correlated to SA/V, Matlab
Statistical Toolbox Analysis of Covariance (ANCOVA)
model (7.0.1.24704 [R14] Service Pack 1) with parallel
lines was used to fit each transcript to the SA/V ratio and
simultaneously account for patient effect.
yij ¼ β0 þ βi þ α SA=Vð Þij þ εij
Where yij is gene expression with i =1, …21 represent-
ing the patient; and j =1, 2 the two samples of lung from
each patient respectively. β0 stands for the overall inter-
cept of the model, βi is the intercept for each patient, α
represent the common slope for the parallel lines for all
patients, and εij the model residual respectively. In this
model the significance of the patient effect is accounted
for by the variation between individual intercepts βi and
its corresponding patient p-value (Ppatient), while slope α
and its corresponding p-value (Pslope) represent the
regression coefficient and its significance with respect to
SA/V, respectively. This model searches for the correla-
tive pattern between gene expression and SA/V common
to all patients as slope α is the same for all patients. It
does not model individual patient SA/V association,
which would be given by the corresponding interaction
effect.
Genes that have significant patient effect, i.e., vary more
between than within patients, can be selected by requiring
Ppatient <0.01. Conversely, those that do not vary sig-
nificantly between the patients can be picked by setting
Ppatient >0.1, for example. Genes that significantly associate
with SA/V can be picked by establishing a p value cut off
for the slope α. It is these latter genes which are of interest
since they relate to the degree of emphysema.
This model was fit individually to all 23,757 probe-
sets on the microarray. Multiplicity adjustments using
Benjamini-Hochberg false discovery rate (FDR) were used
to adjust raw p-values for the slope α. Although 181 genes
showed nominal association with SA/V (P < 0.05), none
passed FDR <0.1. However, real associations could be arti-
ficially diluted by the large number of probe sets tested in
the course of the statistical analysis. One way to overcome
this problem is to perform a conservative selection of
candidate markers and then assess their performance inan independent replication set. This latter step is also
required even for those markers which pass the FDR
cutoff, and constitutes the ultimate check for the validity
of the findings.
Thus, in order to identify markers for subsequent rep-
lication a combination of statistical cutoffs was used.
First, more highly expressed genes that satisfied an aver-
age logIntensity > −1 cutoff were selected. Secondly, the
genes were selected to be significantly associated with
SA/V by requiring Pslope <0.05. Finally, the set was re-
fined by filtering out those with significant patient effect,
by requiring Ppatient >0.1. The reason that the final cutoff
was applied is to allow a replication of the SA/V related
genes in the independent set of 22 patient samples. For
these patients only a single lung sample was available
and adjusting for the patient effect is not possible.
Minimizing the patient effect allows a simple linear
regression model to approximate the slope of the fit
between each of the 181 genes and the corresponding
SA/V ratios in the replication set.
Networks and pathways enrichment analyses
To determine whether the 181 genes which were related
to lung SA/V were enriched for specific biological
processes or were suggestive of specific disease states we
undertook pathway and network analysis using Meta-
Core® from GeneGo Inc. Gene IDs of the 181 transcripts
were used as input for MetaCore®.
Ubuquitination pathway analysis
In this study, we found that a number of deregulated
genes are related to the process of ubiquitination or de-
ubiquitination. To test if there was concordant dysregu-
lation of this pathway at the protein level, we performed
Western analyses on extracts from an additional group
of lung samples. Based on commercial availability of the
antibodies (see below), we selected 9 genes that were
differentially regulated as a function of SA/V from the
list. The genes that were included in this analysis are
shown in Additional file 1: Table S6 with a brief descrip-
tion of their potential role. For the protein quantification
a separate subset of 20 individual lung samples were ex-
amined (See online supplement for details). In addition
to the measurement of protein levels, the proteosome
activity of the lung tissue from 5 of the cases and 5
controls was measured.
Details of the Western blotting and proteosome activ-
ity assays are available in the online supplement.
Results
The analysis identified 181 genes whose level of ex-
pression was related to SA/V in the discovery data set.
Additional file 1: Table S4 lists these genes and the slope,
intercept and p value for their relationship to SA/V. A
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lated to SA/V in the discovery set is shown in Figure 1.
The data are arranged by SA/V. Although the data shown
are the original data without model fitting, a SA/V-correlated
trend is observed when all the samples are combined and
sorted by increasing SA/V values. The level of expression
of these transcripts was then related to the SA/V in the 22
samples which constitute the replication data set. Figure 2
shows that when the genes from the discovery set are
arranged in the same order, the SA/V-correlated trend
is preserved in the replication set.
The slopes relating gene expression to SA/V from the
discovery and the replication sets are compared in Figure 3
which shows that the slopes and direction of effect
obtained from both discovery and replication sets are
consistent, with an overall correlation of 0.6. If we use a
slope p-value cutoff <0.05 in the replication set as a cri-
teria to indicate replication of the initial relationship, 30 of
the 181 genes achieve this level of significance (Table 2).
Figure 4 is identical to Figure 3 except that it only shows
the 30 genes that replicated based on the p value cut off in
the replication sample set. These genes represent potential
markers and candidates for subsequent follow up.
The results of the network and pathways analyses are
shown in Table 3. Using MetaCore, the top significantlyFigure 1 A heat map shows the relationship between the level of exp
the samples in the discovery set. The samples are shown in rows ordere
to SA/V are shown by the yellow bar while those whose expression was poenriched pathways (Minimum P = 2.786E-05) were cell
cycle regulation of G1/S transition, followed by the Immune
response HMGB1/TLR signaling pathway (P = 6.224E-04).
In terms of disease processes, “Starvation” ranked first
(P = 1.042E-04). Gene Ontology (GO) processes’ enrich-
ment presented in Additional file 1: Table S5 identified
processes related to cellular macromolecule metabolism
(P = 1.417E-10), and ubiquitination (P = 2.103E-08) path-
ways as being significantly enriched. Many of these
genes are related to the process of ubiquitination or
deubiquitination.
Interestingly, analysis of the 30 replicated genes showed
significant enrichment in disease biomarkers for muscular
atrophy (p = 4.239E-04) and proteostasis (p = 4.829E-05).
Protein replication
The protein level of five of the 9 ubiquitination-associated
genes (FBXL3, FBXO30, USP38, UBB, and RNF6) was sig-
nificantly different between control and COPD lung tissue
by western analysis (Figure 5). FBXL3, FBXO30, and USP38
were upregulated at the protein level (Figure 5A), which is
opposite in direction to the changes in mRNA. This could
be a reflection of increased protein stability. However
UBB and RNF6 protein were downregulated consistent
with the gene expression profile (Figure 5B). The proteinression of the 181 SA/V-correlated genes (columns) for all 42 of
d by increasing SA/V. Genes whose expression was negatively related
sitively related to SA/V are indicated with the blue bar.
Figure 2 A heat map shows the relationship between the level of expression of the 181 SA/V-correlated genes (columns) for the 22 samples
in the replication set. The samples are shown in rows ordered by increasing SA/V. Genes whose expression was negatively related to SA/V are shown by
the yellow bar while those whose expression was positively related to SA/V are indicated with the blue bar. The pattern is similar to the discovery set.
Figure 3 Slopes of regression for 181 selected genes are
compared between the discovery and replication sets.
The comparison shows a good concordance in the findings.
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TBLR1, and UHRF2) was not significantly altered (data
not shown).
Discussion
Most studies of gene expression in the lungs of patients
who have COPD have compared tissue from subjects with
and without COPD based on lung function [3,5-7].
Although COPD is defined by abnormalities of lung
function there is convincing evidence that there are two
pathological processes that contribute to the functional
impairment [8]; loss of lung elasticity characterized patho-
logically by emphysema and inflammatory narrowing and
obliteration of the small conducting airways [9]. We used
a morphometric measure of emphysema, derived from the
same sample of lung tissue that was used for transcrip-
tomic analysis, as a continuous variable to relate gene
expression to structural changes.











NM_005706 TSSC4 Tumor suppressing subtransferable candidate 4 −0.00037 0.039 −0.00096 0.003
AB067498 Esco1 Establishment of cohesion 1 homolog 1 (S. cerevisiae) 0.00038 0.018 0.00045 0.005
NM_018559 kiaa1704 KIAA1704 0.00040 0.023 0.00065 0.006
NM_004897 MINPP1 Multiple inositol polyphosphate histidine
phosphatase, 1
0.00035 0.033 0.00070 0.006
Contig55580_RC 0.00049 0.029 0.00139 0.006
NM_012180 FBXO8 F-box protein 8 0.00040 0.010 0.00067 0.014
NM_153044 MORC2-
AS1
MORC2 antisense RNA 1 −0.00040 0.022 −0.00054 0.015
NM_022876 SMN2 Survival of motor neuron 2, centromeric 0.00046 0.019 0.00083 0.017
NM_003838 FPGT Fucose-1-phosphate guanylyltransferase 0.00035 0.031 0.00054 0.018
AF055030 PHF10 PHD finger protein 10 0.00036 0.011 0.00067 0.019
NM_007342 NUPL2 Nucleoporin like 2 0.00037 0.047 0.00081 0.019
Contig45624_RC CBLL1 Cbl proto-oncogene-like 1, E3 ubiquitin protein ligase 0.00052 0.018 0.00091 0.020
NM_002103 GYS1 Glycogen synthase 1 (muscle) −0.00033 0.017 −0.00052 0.020
AL359938 MEIS3 Meis homeobox 3; Meis homeobox 3 pseudogene 2 −0.00029 0.040 −0.00054 0.022
NM_014771 RNF40 Ring finger protein 40 −0.00034 0.027 −0.00067 0.024
NM_022877 SMN2 Survival of motor neuron 2, centromeric 0.00046 0.018 0.00077 0.024
Contig41498_RC PTPN4 Protein tyrosine phosphatase, non-receptor type 4 0.00035 0.027 0.00049 0.024
NM_003084 SNAPC3 Small nuclear RNA activating complex, polypeptide 3 0.00044 0.015 0.00075 0.025
NM_013234 EIF3K Eukaryotic translation initiation factor 3, subunit K −0.00025 0.044 −0.00045 0.027
NM_006852 TLK2 Tousled-like kinase 2 0.00021 0.037 0.00032 0.028
X68560 SP3 Sp3 transcription factor 0.00065 0.012 0.00113 0.030
AY007149 CEP350 Centrosomal protein 350 kDa 0.00034 0.029 0.00058 0.030
Contig51940_RC GABPA GA binding protein transcription factor, alpha
subunit 60 kDa
0.00046 0.035 0.00093 0.033
NM_032557 USP38 Ubiquitin specific peptidase 38 0.00048 0.017 0.00073 0.034
NM_015153 PHF3 PHD finger protein 3 0.00060 0.034 0.00057 0.036
NM_004162 RAB5A RAB5A, member RAS oncogene family 0.00030 0.045 0.00048 0.037
NM_022875 SMN2 Survival of motor neuron 2, centromeric 0.0004843 0.015 0.00071 0.039
NM_005316 GTF2H1 General transcription factor IIH, polypeptide 1,
62 kDa
0.00042 0.010 0.00069 0.039
Contig53191_RC GPD2 Glycerol-3-phosphate dehydrogenase 2
(mitochondrial)
0.00043 0.043 0.00069 0.041
NM_017411 SMN2 Survival of motor neuron 2, centromeric 0.00048 0.029 0.00071 0.044
*All FDR values were >0.1 in the discovery samples.
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samples from each individual, one with the highest and
one with the lowest SA/V ratios, allowed us to account
for patient-to-patient variability. An advantage of this
design is that the demographic distribution of patients is
of much lesser concern than for between- subject com-
parisons, where serious attention must be given to
stratification and balancing of patients with respect to
potentially confounding demographic attributes. Tran-
scripts that significantly correlated with SA/V ratio afteradjusting for patient gene expression variation constitute
relevant biological candidates.
Although most studies of transcriptional profiles of
COPD patients have focused on expression changes as-
sociated with disease status or level of lung function,
Campbell et al. recently reported the results of a study
examining gene expression as related to alterations in
local lung architecture [10]. This study examined the
correlation of gene expression with Lm (Lm =mean linear
intercept, a microscopic measure of emphysema directly
Figure 4 Slopes of regression for the 30 genes that replicated
at p < 0.05 in the replication data set. The slopes for the replication
data are on the x axis and those from the discovery set are on
the y axis.
Table 3 MetaCore pathway and network analysis results
for 181 genes related to emphysema
Pathway analysis
# Maps p-value
1 Cell cycle_Regulation of G1/S transition* 2.786E-05
2 Cell cycle_Role of SCF complex in cell cycle regulation* 3.259E-04
3 Cell cycle_ESR1 regulation of G1/S transition* 4.803E-04
4 Immune response_ HMGB1/TLR signaling pathway* 6.224E-04




2 Cystadenocarcinoma, Serous 1.066E-03
3 Cystadenocarcinoma 1.328E-03
4 Neoplasms, Cystic, Mucinous, and Serous 1.401E-03
5 Neoplasms, Complex and Mixed 1.497E-03
6 Motor Neuron Disease 3.125E-03
Process Networks
# Networks p-value
1 Proteolysis_Proteolysis in cell cycle and apoptosis* 7.634E-04
2 Cell cycle_Mitosis* 9.314E-04
3 Cell cycle_S phase 1.896E-03
4 Transcription_mRNA processing 2.716E-03
5 Transcription_Chromatin modification 5.222E-03
6 Signal Transduction_BMP and GDF signaling 8.269E-03
7 Cell cycle_G1-S 1.407E-02
8 Cytoskeleton_Spindle microtubules 1.531E-02
9 Signal transduction_NOTCH signaling 1.720E-02
10 Cell cycle_G2-M 3.453E-02
*Donates that the enrichment for pathways, diseases and networks is
significant at FDR <0.1.
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the design of Campbell et al. and our study, we found no
genes in common. While this is undoubtedly due, at least
in part, to differences in patient populations, the specifics
of sample preparation and/or the expression platform
(Agilent versus Affymetrix), another factor may have been
experimental design. Two of the eight lungs in the study
of Campbell et al. were from normal individuals, and these
had substantially lower Lm than in COPD. This creates a
potential bias such that many genes reported as correlat-
ing with Lm were also dependent on COPD status. While
this covariate was technically accounted for with the in-
clusion of a random patient effect in the fitted mixed
models, the authors did not remove genes that had a
significant patient effect as we did. Indeed, 78 of 126 genes
reported by Campbell et al. were differentially expressed in
normal donors compared to COPD patients (p-value <0.001
by student’s T-Test) and 65 of these genes also had a signifi-
cant patient effect in our study (p-value of alpha <0.05).
Thus, differences in results may indicate that the results
of Campbell et al. reflect a mix of gene expression changes
due to emphysema and disease status.
The most significantly enriched pathways we identified
relate to the regulation of G1/S transition, and to high
mobility group box protein 1/toll like receptor (HMGB1/
TLR) signaling. Further discussion of the potential role of
these genes is included in the online supplement.
Many of the genes identified as being related to SA/V
are involved in the handling of proteins. Cellular protein
homeostasis, also known as proteostasis, involves the
control of the conformation, concentration, binding in-
teractions, and localization of individual proteins withinand outside the cell. The proteostasis network refers to
the >2000 genes in mammals encoding proteins that
work together as a system to control protein concentra-
tion and conformation through interactions of the prote-
ome with chaperone systems and folding enzymes as well
as via protein degradation mediated by the ubiquitin
proteasome system [11].
There is evidence that an imbalance in proteostasis
contributes to certain diseases [12]. Our data implicating
genes involved in the handling of protein suggests that
an imbalance in the synthesis and degradation of protein
may be involved in the genesis of emphysema. This idea
is not new; Min et al. used immunohistchemistry to
examine the expression of proteins involved in protein
processing and apoptosis in the lungs of individuals with
varying severity of COPD. They show accumulation of
poly-ubiquitinated proteins in insoluble aggregates in
the lungs of subjects with emphysema [13]. Cantin and
Figure 5 (See legend on next page.)
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Figure 5 Protein expression of ubiquitination genes in lung tissues from control and COPD patients. Lung homogenates were prepared
and Western blotting was performed to examine protein levels with the antibodies specified. β-actin was probed as a protein loading control.
Protein levels were quantified by densitometric analysis wit the NIH ImageJ program and normalized to β-actin expression. A: results for FBXL3,
FBXO30, and USP38 showing upregulation in COPD. B: results for UBB and RNF6 showing downregulation in COPD. Data are means ± SE, and
significance was determined by Students’ t-tests.
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portant in obstructive lung diseases [14].
In particular, genes involved in the ubiquitin-proteosome
pathway were significantly over-represented in the present
study. The ubiquitin-proteasome system (UPS) serves a
crucial function in protein quality control to maintain cel-
lular proteostasis through the degradation of misfolded/
damaged proteins and the turnover of normal short-lived
regulatory proteins. Recently, impairment of the UPS has
been reported in several lung diseases, including COPD/
emphysema and pulmonary fibrosis [15,16]. It was shown
that lung tissue from COPD patients with severe emphy-
sema has aberrant accumulation of ubiquitinated proteins
[13], a phenomenon commonly observed in protein
conformational diseases, including neurodegenerative
and heart diseases [17,18].
Increased abundance of ubiquitinated conjugates could
be the result of decreased proteasome activity and/or in-
creased protein ubiquitination. Upon exposure to cigarette
smoke, the proteolytic activities of the proteasome in hu-
man alveolar epithelial cells and mouse lung were mark-
edly decreased [19,20]. We also demonstrated a consistent
reduction of all three proteasome activities (chymotryp-
sin-, trypsin-, and caspase-like) in human COPD lungFigure 6 Proposed model of dysregulation of the ubiquitin-proteas
emphysema/COPD. Oxidative stress and inflammation induced by smo
ubiquitination-related genes and impairment of the proteasome function. Ac
production and decreased degradation causes further damage of the proteaso
of the UPS results in apoptosis, inflammation, and matrix remodeling, pathoge
can also cause compensatory upregulation of genes associated with the UPS.tissues as compared to control lung (Additional file 2:
Figure S3), although the latter two changes did not reach
statistical significance probably due to small sample size.
In addition to disposal of misfolded/damaged proteins,
the UPS also plays a key role in the regulation of many
fundamental cellular functions, including apoptosis, cell
cycle regulation, antigen processing, and transcriptional
regulation via controlling the degradation of normal regu-
latory proteins [21-23]. Both FBXL3 and FBXO30 are
F-box proteins, critical components of the SCF (SKP1-
cullin-F-box) E3 ligases which are involved in the degradation
of signal and cell cycle proteins [24]. Upregulation of these
proteins suggest a role for apoptosis and cell cycle arrest
in the pathogenesis of emphysema. USP38 is a deubiquiti-
nating enzyme and was recently identified as a susceptibil-
ity gene for asthma [25]. Although the exact targets of
USP38 remain unclear, it is speculated that upregulation
of USP may reflect a cellular response to inflammation
and injury. The gene UBB encodes polyubiquitin precur-
sor protein which is processed by deubiquitinating en-
zymes to produce a single ubiquitin moiety and ribosomal
proteins [26]. Down-regulation of UBB will lead to de-
creased availability of the free ubiquitin pool, thereby
resulting in reduced protein ubiquitination and subsequentome system leading to the pathogenesis and progression of
ke, genetic or environmental insults result in dysregulation of
cumulation of abnormal proteins in the lung as a result of increased
me function and dysregulation of UPS-related genes. Aberrant regulation
nic characteristics of emphysema/COPD. Damaged proteasome function
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Gene) finger domain E3 ligase and LIM kinase 1 (LIMK1)
has been identified as a substrate of RNF6 [27]. LIMK1, a
serine/threonine kinase involved in the regulation of actin
polymerization and microtubule disassembly, was shown
to promote the disruption of endothelial barrier and
inflammatory infiltration in mouse lung [28]. It is there-
fore plausible to assume that downregulation of RNF6
plays a role in the chronic inflammation of COPD.
Figure 6 summarizes the proposed mechanisms by
which smoke and ROS-mediated modulation of the UPS
could contribute to the pathogenesis and progression of
COPD by participating in the regulation of apoptosis, the
inflammatory response, and interstitial fibrosis. Future
studies are required to address the function and regulation
of this system in COPD/emphysema and to further
explore the specific mechanisms involved.
There are several limitations to this study. The sample
size is relatively small and thus the possibility of false
negative or positive associations is real. We addressed this,
in part, by using one portion of the samples as a derivation
set and one portion as a replication set. Figure 3 shows
that the level of expression of 164 of the 181 genes were
associated with SA/V in the same direction in the replica-
tion set as in the derivation set and 30 of the 181 genes
showed significant (p < 0.05) association with SA/V in
the replication set (with the same direction of effect –
see Figure 4). We used all 181 genes, not only the 30
that replicated, to examine for enriched networks using
MetaCore®. We feel we are justified in this approach
given that the vast majority of expression changes were
in the same direction. Another limitation is the fact that
samples were done in two batches which had a substan-
tial systematic effect on gene expression. Although we
adjusted for this bias statistically, it is possible that some
true positive associations could have been missed due to
this adjustment.
Finally, changes in gene expression do not confirm
that these genes are causal to emphysema. Some of the
changes could be a consequence of the molecular pro-
cesses that result from the development of emphysema.Conclusions
The analysis approach adopted in this study allowed
examination of the relationship between gene expres-
sion and SA/V, a measure of tissue destruction by em-
physema. Gene set annotation and pathway analyses
implicated genes involved in protein ubiquitination
and the proteasome pathways and protein analysis con-
firmed the abnormal accumulation of protein-ubiquitin
conjugates and the altered expression of genes involved
in protein ubiquitination in the lungs of obstructed
smokers.Availability of supporting data
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